• Avoid buying Alphabet (GOOGL/GOOG) for now; wait for more stable Search and advertising trends and clearer returns on its AI spending.
• Research Genmab (GMAB) further: the speaker called its result “incredible,” but gave no specific recommendation or valuation.
• The comments provide no actionable trade on Eli Lilly (LLY), Moderna (MRNA), or SanDisk.

Alphabet (GOOGL, GOOG)

• Mixed results: Google Cloud was described as delivering “unbelievable” results, while subscriptions were a little light, the network business had been weak, YouTube growth was slow, and Search missed the speaker’s expectations by about $1 billion.
• Revenue grew 25% year over year, but the speaker said Search growth of 12% raised concerns about AI’s effect on Google’s core business.
• Capital spending reached a record of about $51.4 billion for the quarter. The speaker said quarterly free cash flow was negative $9 billion, following negative $6 billion in the prior quarter, compared with roughly $20 billion per quarter before the recent spending surge. They also noted that trailing-twelve-month free cash flow was about $20 billion.
• The speaker questioned whether the spending will generate enough revenue: revenue had not grown as quickly as property, plant, and equipment, which the speaker associated with infrastructure such as GPUs. They cautioned that Google may need to keep increasing capital spending just to maintain its position.
• The core concern was the risk AI poses to Google’s advertising business. The speaker said ads could be difficult to sustain over the next 10–20 years, and suggested that more aggressive ad monetization could harm the customer experience.
• The speaker said they wouldn’t buy Google at this point, citing uncertainty about management’s AI investments and the need to see more stable ad-revenue trends. They also noted a roughly $3.2 trillion market capitalization and said the company’s valuation looked demanding under the current, unusually low free-cash-flow conditions, while acknowledging those conditions might not persist.
• Counterpoints included strong Cloud results, rising revenue per employee, and the potential for AI infrastructure investments to generate future revenue. The speaker also described Google’s TPUs as impressive, but said the business model was hard to assess.

Takeaways

• The discussion presents Alphabet as a high-stakes AI transition story: Cloud strength and infrastructure investments are positives, but Search and advertising remain central uncertainties.
• The speaker’s stated stance was cautious: wait for more stable ad-revenue trends and clearer evidence that the AI spending is producing returns before making a judgment on the stock.
• The key issues raised were record capital spending, weaker near-term free cash flow, and the possibility that AI could disrupt Google’s most profitable business.

Eli Lilly (LLY)

• Lilly was mentioned briefly. The speaker said they didn’t think the quarter was that good, while also describing margins as fine and pointing to a significant year-over-year drop in selling, general, and administrative expenses as evidence of expense management.
• No specific valuation, price target, or investment recommendation was given.

Takeaways

• The limited comments were mixed: the speaker was unimpressed with the quarter overall but acknowledged favorable expense control.
• The transcript does not provide enough detail to draw a broader investment conclusion about Lilly.

Genmab (GMAB)

• Genmab was described as having an “incredible” result and was flagged as a company the speaker wanted to examine further.
• The speaker referred to a new major cancer player as being “kind of like Moderna but real”; the surrounding discussion appears to connect this remark to Genmab, but no specific drug, financial result, or recommendation was provided.

Takeaways

• The comments convey positive interest, but they are too brief to support a specific investment conclusion.
• Further research would be needed to understand the company’s products, results, and risks; none were detailed in the transcript.

Moderna (MRNA)

• Moderna was used as a comparison in a brief comment about a cancer player. The speaker did not discuss Moderna’s own business, results, or prospects.

Takeaways

• The transcript offers no standalone investment view or recommendation on Moderna.

SanDisk

• SanDisk was mentioned in connection with what the speaker called bad news related to “Kyosha Nuse,” which may refer to Kioxia. The transcript did not explain the news or its expected effect on SanDisk.

Takeaways

• The mention suggests a possible negative development for SanDisk, but the transcript does not provide enough context to assess its significance or support an investment conclusion.

AI Infrastructure and Cloud

• Google’s strong Cloud performance was presented as a positive, while its record capital spending highlighted the scale of investment required to build AI infrastructure.
• The speaker noted that Google’s TPUs could support future revenue, but questioned whether the company’s infrastructure spending would generate sufficient returns.
• OpenAI was mentioned as a competitor, and the speaker said its ad revenue was “doing fine.” No investment in OpenAI was discussed.

Takeaways

• The discussion points to a tension in AI investing: demand for Cloud and AI infrastructure may be strong, but very high spending does not guarantee attractive returns.
• For Alphabet, the speaker emphasized watching whether AI-related investment translates into durable revenue growth without undermining the advertising business.

Rotation Into Safer Stocks

• The speaker acknowledged a market theme of rotation into safer stocks, but did not name specific beneficiaries or make a recommendation.

Takeaways

• This was presented as a broad market observation, not a specific investment opportunity.